Company Overview - IRadimed Corporation (NASDAQ: IRMD) is a small company focused on developing, manufacturing, and selling MRI-compatible products, generating a consistent revenue stream [1] - The company has demonstrated steady revenue growth, achieving 14 consecutive quarters of growth [1] Industry Insights - The company operates within the medical device industry, specifically targeting MRI-compatible technologies, which is a niche market with potential for continued demand [1]

Core Insights - Iradimed Corporation will participate in the 37th Annual Roth Conference, hosting one-on-one meetings between management and investors on March 17 and 18, 2025 [1] Company Overview - Iradimed Corporation is a leader in developing innovative MRI-compatible medical devices, including the design, manufacture, marketing, and distribution of these devices and related services [2] - The company is the only provider of a non-magnetic intravenous infusion pump system designed for safe use during MRI procedures, addressing dangers associated with standard infusion pumps [3] Product Highlights - The MRidium® MRI-compatible IV infusion pump system features a non-magnetic ultrasonic motor and non-ferrous parts, ensuring safe and predictable delivery of anesthesia and IV fluids during MRI procedures [3] - The 3880 MRI-compatible patient vital signs monitoring system operates in magnetic fields up to 30,000 gauss, allowing for continuous monitoring of critically ill patients during MRI scans [4] - Key features of the IRADIMED 3880 include wireless ECG, wireless SpO2, non-magnetic respiratory CO2 monitoring, and advanced anesthetic agent measurement capabilities [4]

Regulatory Risks - The company received notice of examination from the U.S. Internal Revenue Service (IRS) for the tax year ended December 31, 2021, which could adversely affect financial results [204]. - The medical device industry is subject to extensive government regulation, primarily by the FDA, which could result in delays or increased costs for product development and marketing [208]. - The company is subject to healthcare fraud and abuse regulations that could result in significant liability and require changes to business practices [224]. - Regulatory changes could restrict the company's ability to manufacture and sell products, leading to higher costs or lower revenues [211]. - The company may face challenges in maintaining compliance with FDA and other regulatory requirements, which could disrupt business operations [230]. - The development and use of Artificial Intelligence (AI) presents risks that could impact operations, including compliance with evolving laws and regulations [207]. Intellectual Property Risks - The company relies on a combination of patents, trademarks, trade secrets, and contractual provisions to protect its intellectual property, but cannot guarantee the adequacy of these measures [232]. - The transition to a "first inventor to file" system in the U.S. may complicate the patent application process, potentially affecting the company's competitive advantage [234]. - The company faces risks related to the enforcement of its intellectual property rights, which could result in substantial expenses and impact its ability to commercialize products [241]. - Patent litigation and other intellectual property proceedings could lead to significant costs and management distraction, adversely affecting the company's competitive position [245]. - The company may need to engage in costly litigation to defend its intellectual property rights, which could divert resources and impact financial performance [246]. Financial Performance and Dividends - The company has declared a regular quarterly cash dividend of $0.17 per share, but future dividends will depend on various factors including cash generation and capital needs [254]. - The company may need to raise additional funds through equity or debt securities, which could dilute existing shareholders and affect stock price [256]. - Compliance with public company regulations increases legal and financial costs, potentially diverting management's attention from core business activities [257]. Market and Currency Risks - Sales to customers outside of the U.S. accounted for approximately 17% of net revenues in 2024, with expectations for future growth from international markets [213]. - The company operates in approximately 80 countries, with most sales and purchases denominated in U.S. Dollars, exposing financial results to foreign currency exchange rate fluctuations [341]. - The company faces foreign currency risks primarily related to the Japanese Yen, with potential fluctuations in net income due to transaction gains and losses from Yen-denominated accounts payable [342]. - A 10% change in the U.S. Dollar's strength relative to the Yen would have an immaterial impact on net income for the year ended December 31, 2024 [342]. - Interest income is sensitive to changes in U.S. market interest rates, with an expected change of approximately $489,000 in interest income for a 100 basis point change from levels at December 31, 2024 [343]. Ownership and Influence - The founder, Roger Susi, owns approximately 36% of the company's outstanding common stock, allowing him to exert significant influence over shareholder matters [260]. Product Liability - The company carries third-party product liability insurance with maximum coverage of $5 million, but faces a deductible of $50,000 per occurrence and $150,000 in the aggregate [217]. Negative Publicity - Negative publicity related to product safety issues could materially affect the company's financial position and market value [218].

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was reported at $19.4 million, an increase of 11% compared to Q4 2023 [16] - For fiscal year 2024, revenue increased 12% to $73.2 million [16] - Gross profit for Q4 2024 was $76.1 million, with a gross margin of 76.1%, slightly down from 76.9% in Q4 2023 [17][18] - GAAP diluted earnings per share increased 11% from Q4 2023 to $0.40 per share [21] - Non-GAAP adjusted net income for Q4 2024 was $0.44 per diluted share, up from $0.39 in Q4 2023 [21] Business Line Data and Key Metrics Changes - Domestic sales increased 21% to $16.5 million, while international sales decreased 24% to $2.9 million [17] - Device revenue increased 12% to $14.3 million in Q4 2024, driven by a 34% increase in pump revenue [17] - Revenue from disposables and services increased by 9% for both Q4 2024 and fiscal 2024 [17] Market Data and Key Metrics Changes - Domestic revenue accounted for approximately 85% of total revenue in Q4 2024, compared to 78% in Q4 2023 [17] - The company expects to see strong performance in the first half of 2025, supported by a strong backlog [47] Company Strategy and Development Direction - The company plans to focus on monitor sales in 2025, with adjustments made to sales team incentives [26][29] - A new facility is under construction, with completion expected by June 2025 [12][23] - The company anticipates launching the new 3870 MR IV pump in mid-2025, with significant sales expected in 2026 [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving FDA clearance for the new pump by mid-2025, despite potential delays [10] - The company expects revenue guidance for Q1 2025 to be between $19.2 million and $19.4 million [13] - Management noted that tariffs on certain components would have a negligible impact on gross margins [60] Other Important Information - Operating expenses for Q4 2024 were $9 million, or 46% of revenue, compared to $8.3 million, or 47% of revenue, in Q4 2023 [18] - Cash from operations increased to $6 million for Q4 2024, up from $3.9 million in Q4 2023 [22] Q&A Session Summary Question: Will the sales force focus more on the monitor business in 2025? - Management confirmed that the sales team will indeed focus more on the monitor business, expecting significant impacts in 2025 [26][27] Question: Has there been a shift in focus of the sales force? - Management indicated that minor adjustments were made to sales goals, which have already shown positive results in Q4 [29] Question: What are the expectations for R&D spending and gross margins in 2025? - R&D spending is expected to remain consistent, with gross margins projected to be in the 76% to 77% range [31][33] Question: How is the backlog expected to change throughout the year? - Management noted that the backlog is currently strong, particularly for pumps, but expects monitors to gain a larger share as the year progresses [47] Question: How many pumps are expected to be renewed starting in 2026? - Management anticipates replacing about 800 to 1,000 systems, leading to a significant increase in pump sales [53][54]

Company Performance - iRadimed reported quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.45 per share, but showing an increase from $0.39 per share a year ago, resulting in an earnings surprise of -2.22% [1] - The company posted revenues of $19.39 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.57% and increasing from $17.45 million year-over-year [2] - Over the last four quarters, iRadimed has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - iRadimed shares have gained about 10% since the beginning of the year, outperforming the S&P 500's gain of 2.9% [3] - The current consensus EPS estimate for the coming quarter is $0.42 on revenues of $19.46 million, and for the current fiscal year, it is $1.72 on revenues of $80.81 million [7] - The estimate revisions trend for iRadimed is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which iRadimed belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - IRADIMED CORPORATION reported record financial results for Q4 2024, marking the fourteenth consecutive quarter of revenue growth, driven by strong demand for its MRI-compatible IV infusion pumps and patient monitoring systems [2][5][8] - The company announced an increase in its quarterly cash dividend from $0.15 to $0.17 per share, reflecting its strong financial position and commitment to returning value to shareholders [2][4] - For 2025, the company expects revenue between $78.0 million and $82.0 million, with GAAP diluted earnings per share projected between $1.55 and $1.65 [3][14] Financial Performance - For Q4 2024, the company reported revenue of $19.4 million, an increase of 11% from $17.5 million in Q4 2023, and net income of $5.1 million, up 13% from $4.5 million in the same period last year [5][8] - For the full year 2024, total revenue reached $73.2 million, a 12% increase from $65.6 million in 2023, with net income also rising by 12% to $19.2 million [7][9] - Non-GAAP net income for Q4 2024 was $5.7 million, a 14% increase from $5.0 million in Q4 2023, with non-GAAP diluted earnings per share at $0.44, up 13% [6][40] Revenue Breakdown - In Q4 2024, the revenue from MRI-compatible IV infusion pump systems was $7.57 million, up from $5.64 million in Q4 2023, while revenue from MRI-compatible patient vital signs monitoring systems was $6.57 million, slightly down from $6.85 million [10] - For the full year 2024, the revenue from IV infusion pump systems was $26.6 million, compared to $19.6 million in 2023, while monitoring systems generated $24.4 million, down from $25.4 million [10][11] Cash Flow and Investments - Cash flow from operations for Q4 2024 was $6.0 million, a 54% increase from $3.9 million in Q4 2023, and for the full year, it was $25.6 million, a 90% increase from $13.5 million [12][12] - The company is investing approximately $5.5 million in cash in 2025 to complete the construction of a new facility in Orlando, Florida, which is expected to support future growth [13] Guidance and Future Outlook - The company anticipates revenue for Q1 2025 to be between $19.2 million and $19.4 million, with GAAP diluted earnings per share expected to be between $0.35 and $0.39 [3][14] - The guidance for non-GAAP diluted earnings per share for 2025 is projected to be between $1.71 and $1.81 [14][15]

Core Viewpoint - Iradimed Corporation is set to release its 2024 fourth quarter financial results on February 13, 2025, and will host a conference call to discuss these results [1][2]. Company Overview - Iradimed Corporation specializes in developing innovative MRI-compatible medical devices, notably a non-magnetic intravenous infusion pump system designed for safe use during MRI procedures [3]. - The company was the first to create an infusion delivery system that mitigates risks associated with standard infusion pumps, which contain magnetic components that can interfere with MRI operations [3]. - The patented MRidium® MRI-compatible IV infusion pump utilizes a non-magnetic ultrasonic motor and non-ferrous parts to ensure safe and reliable delivery of anesthesia and IV fluids during MRI scans [3]. Product Features - The Iradimed 3880 MRI-compatible patient vital signs monitoring system is designed with non-magnetic components, allowing it to function in magnetic fields up to 30,000 gauss, ensuring patient safety during MRI procedures [4]. - This system features wireless ECG, SpO2 monitoring, non-magnetic respiratory CO2 measurement, and both invasive and non-invasive blood pressure monitoring, among other capabilities [4]. - The compact and lightweight design of the Iradimed 3880 allows for continuous monitoring of critically ill patients, reducing the time they spend away from critical care units [4].

Financial Results - iRadimed Corporation announced preliminary unaudited revenues for Q4 2024 and full-year 2024 on January 10, 2025[4] - The press release regarding the financial results is furnished as Exhibit 99.1 to the Current Report on Form 8-K[4] Company Information - The company is listed on the NASDAQ Capital Market under the trading symbol IRMD[3]

Core Insights - Iradimed Corporation reported preliminary unaudited revenue for Q4 and full-year 2024, indicating strong growth and record-breaking performance [2][3][7] - The company anticipates Q4 2024 revenue between $19.2 million and $19.4 million, reflecting a year-over-year growth of 10% to 11% and a sequential growth of 5% to 6% [2][7] - Full-year 2024 revenue is expected to be approximately $73.1 million to $73.3 million, compared to $65.6 million in the previous year, representing an 11% to 12% year-over-year growth [2][7] Financial Performance - Q4 2024 revenue is projected to be the highest quarterly revenue to date for the company, marking the 14th consecutive quarter of record revenues [3] - Orders booked in Q4 2024 exceeded shipments, resulting in a robust backlog and enhanced visibility for 2025 [3] Product Offerings - Iradimed is a leader in developing MRI-compatible medical devices, including the MRidium® MRI compatible IV infusion pump system and the 3880 MRI-compatible patient vital signs monitoring system [4][5][6] - The MRidium® system is designed to safely deliver anesthesia and IV fluids during MRI procedures, addressing safety concerns associated with standard infusion pumps [5] - The 3880 system allows for continuous monitoring of vital signs in high magnetic fields, enhancing patient safety and care during MRI scans [6] Upcoming Events - The company is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 5:15 p.m. Pacific Time [3][7]

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for successful short-term investing, highlighting that price movements should be supported by strong fundamentals and positive earnings estimates [1][2]. Group 1: Stock Performance and Trends - iRadimed (IRMD) has shown a solid price increase of 9.7% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - The stock has also maintained a price increase of 1.4% over the last four weeks, suggesting that the upward trend is still intact [5]. - Currently, IRMD is trading at 81.5% of its 52-week high-low range, indicating a potential breakout opportunity [6]. Group 2: Fundamental Strength - IRMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term performance [7]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like IRMD that are on an uptrend supported by strong fundamentals [3]. - It also mentions that there are over 45 Zacks Premium Screens available for investors to find stocks that align with their investment strategies [8].